A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.